{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T02:26:28Z","timestamp":1779157588101,"version":"3.51.4"},"reference-count":13,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100022312","name":"Soci\u00e9t\u00e9 Fran\u00e7aise d'H\u00e9matologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.autrev.2023.103469","type":"journal-article","created":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T12:04:05Z","timestamp":1698149045000},"page":"103469","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Serum calprotectin is a marker of disease activity in Giant cell arteritis"],"prefix":"10.1016","volume":"22","author":[{"given":"Antoine","family":"Saut","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Paclet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Candice","family":"Trocm\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Toussaint","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Bocquet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Bouillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athan","family":"Baillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2023.103469_bb0005","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/path.1660","article-title":"Early recruitment of phagocytes contributes to the vascular inflammation of giant cell arteritis: phagocytes in giant cell arteritis","volume":"204","author":"Foell","year":"2004","journal-title":"J Pathol"},{"issue":"Supplemental","key":"10.1016\/j.autrev.2023.103469_bb0010","first-page":"S756","article-title":"Distinct patterns of gene expression in temporal artery biopsies associated with pathogenesis of giant cell arteritis","volume":"54","author":"Hajj-Ali","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2023.103469_bb0015","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/kez034","article-title":"Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis","volume":"58","author":"van Sleen","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2023.103469_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102428","article-title":"Serum amyloid a as a marker of disease activity in Giant cell arteritis","volume":"19","author":"Dartevel","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2023.103469_bb0025","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2023.103469_bb0030","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/RHU.0000000000000729","article-title":"Serum S100 proteins as a marker of disease activity in large vessel Vasculitis: JCR","volume":"24","author":"Springer","year":"2018","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.autrev.2023.103469_bb0035","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13075-022-02887-7","article-title":"Calprotectin (S100A8\/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapy","volume":"24","author":"Gernert","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2023.103469_bb0040","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/03009740410009931","article-title":"A longitudinal study of calprotectin in patients with polymyalgia rheumatica or temporal arteritis: relation to disease activity","volume":"34","author":"Brun","year":"2005","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2023.103469_bb0045","doi-asserted-by":"crossref","first-page":"1001025","DOI":"10.3389\/fimmu.2022.1001025","article-title":"From bench to bedside: calprotectin (S100A8\/S100A9) as a biomarker in rheumatoid arthritis","volume":"13","author":"Inciarte-Mundo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103469_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2020.08.003","article-title":"Serum calprotectin is increased in early axial spondyloarthritis with sacroiliitis and objective signs of inflammation: results from the DESIR cohort","volume":"88","author":"Romand","year":"2021","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2023.103469_bb0055","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3389\/fimmu.2019.00305","article-title":"Biomarkers for diagnosis of axial Spondyloarthritis, disease activity, prognosis, and prediction of response to therapy","volume":"10","author":"Maksymowych","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2023.103469_bb0060","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/art.39814","article-title":"Association of serum calprotectin (S100A8\/A9) level with disease relapse in proteinase 3\u2013antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"69","author":"Pepper","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2023.103469_bb0065","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003198","article-title":"Serum calprotectin levels do not predict subsequent relapse in rheumatoid arthritis in remission: a post-hoc analysis of STRASS study","volume":"9","author":"Romand","year":"2023","journal-title":"RMD Open"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223002033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997223002033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:31:06Z","timestamp":1761600666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997223002033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1568997223002033"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103469","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum calprotectin is a marker of disease activity in Giant cell arteritis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2023.103469","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103469"}}